TABLE V.
Reasons for all reported holds in 43 patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in Manitoba approved for treatment with ibrutinib between August 2014 and March 2017
| Reason | Patients affected [n (%)] | Duration (days) | ||
|---|---|---|---|---|
| Median | IQR | Range | ||
| Surgery | 29 (34.52) | 3.50 | 6.00 | 0–41 |
| Infection | 15 (17.86) | 7.00 | 18.00 | 1–403 |
| Cytopenia | 7 (8.33) | 99.00 | 301.00 | 2–357 |
| Gastrointestinal effects | 7 (8.33) | 11.00 | 32.00 | 1–83 |
| Musculoskeletal problem | 7 (8.33) | 11.00 | 302.00 | 2–308 |
| Cardiac effects | 5 (5.95) | 8.00 | 52.00 | 4–92 |
| Bruising and bleeding | 4 (4.76) | 9.00 | 15.00 | 2–24 |
| Medication interaction | 3 (3.57) | 6.00 | 9.300 | 3–12 |
| Rash | 3 (3.57) | 6.00 | 6.00 | 3–9 |
| Neurologic effects | 2 (2.38) | 32.50 | 47.00 | 9–56 |
| Radiation treatment | 1 (1.19) | 17.00 | 0 | 17–17 |
| Transformation | 1 (1.19) | 56.00 | 0 | 56–56 |
IQR = interquartile range.